Cargando…
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders. Here, the elucidation of key pathogenic factors such as IL...
Autores principales: | Solimani, Farzan, Meier, Katharina, Ghoreschi, Kamran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901833/ https://www.ncbi.nlm.nih.gov/pubmed/31849996 http://dx.doi.org/10.3389/fimmu.2019.02847 |
Ejemplares similares
-
Case Report: Apremilast for Therapy-Resistant Pemphigus Vulgaris
por: Meier, Katharina, et al.
Publicado: (2020) -
Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
por: Solimani, Farzan, et al.
Publicado: (2021) -
Pemphigus Foliaceus Autoantibodies Induce Redistribution Primarily of Extradesmosomal Desmoglein 1 in the Cell Membrane
por: Hiermaier, Matthias, et al.
Publicado: (2022) -
Detection of rare autoreactive T cell subsets in patients with pemphigus vulgaris
por: Polakova, Alexandra, et al.
Publicado: (2022) -
Editorial: JAK inhibition in autoimmune and inflammatory diseases
por: Telliez, Jean-Baptiste, et al.
Publicado: (2022)